Analysis of Volatile Organic Compounds by Electronic Noses in Hospitalised Patients for an Infection by SARS-COV-2 (COVID-19)
Launched by HOPITAL FOCH · May 6, 2020
Trial Information
Current as of August 02, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients infected by SARS-CoV-2 whose medical condition warrants hospitalisation (out of intensive care) for oxygen therapy less or equal to 4 l/min
- • Patients must be 18 years of age or older
- • Fluent in the French language
- • Have signed a consent form
- • Being affiliated with healthcare insurance
- Exclusion Criteria:
- • Pregnant woman
- • Patient deprived of liberty by judicial or administrative decision
About Hopital Foch
Hospital Foch is a leading healthcare institution located in Suresnes, France, renowned for its commitment to innovative medical research and patient-centered care. As a prominent clinical trial sponsor, Hospital Foch actively engages in the development of new therapeutic approaches across various medical disciplines, facilitating cutting-edge studies that aim to enhance treatment outcomes and improve patient quality of life. With a multidisciplinary team of experienced researchers and healthcare professionals, the hospital fosters a collaborative environment that prioritizes ethical standards and scientific rigor, ensuring the highest quality in clinical trial execution and patient safety.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Suresnes, , France
Patients applied
Trial Officials
Hélène Salvator
Principal Investigator
Pneumology unit
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials